Crossmark

Durable responses to frontline 177Lu-PSMA radioligand therapy in patients with metastatic castration resistant prostate cancer (mCRPC)

Published Online: 2025-06-23

Authors

Jokar, Narges

Jafari, Esmail

Rekabpour, Seyed Javad

Zohrabi, Farshad

Ahmadzadehfar, Hojjat

Assadi, Majid
License Information

Text and Data Mining valid from 2025-06-23

Version of Record valid from 2025-06-23
More Information

Article History

Received: 29 December 2024

Accepted: 11 June 2025

First Online: 23 June 2025

Declarations

:

: The authors declare no competing interests.

Document is current